Skip to main content
main-content

18-05-2022 | Oncology | Video

ELCC 2022 | IMpower010 trial update confirms adjuvant atezolizumab efficacy for patients with high PD-L1 expression

Nasser Altorki talks through the high PD-L1 expression sub-analysis findings from the IMpower010 trial of adjuvant atezolizumab versus best supportive care for stage II–IIIA NSCLC (5:37).